Old Web
English
Sign In
Acemap
>
authorDetail
>
Marie Payton
Marie Payton
MDMX
Mdm2
Cancer research
Peptide
Medicine
3
Papers
75
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type
2018
Blood
David A. Sallman
Uma Borate
Elizabeth H. Cull
William B. Donnellan
Rami S. Komrokji
Ulrich Steidl
Maria M. Corvez
Marie Payton
D. Allen Annis
Dawn Pinchasik
Manuel Aivado
Amit Verma
Show All
Source
Cite
Save
Citations (16)
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma
2018
Blood
Andrei R. Shustov
Steven M. Horwitz
Jasmine Zain
Manish R. Patel
Sanjay Goel
Lubomir Sokol
Funda Meric-Bernstam
Geoffrey I. Shapiro
Sunita D. Nasta
Murali Janakiram
David M. Weinstock
Ronald Korn
Marie Payton
D. Allen Annis
Dawn Pinchasik
Manuel Aivado
A. Mehta
Show All
Source
Cite
Save
Citations (4)
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
2017
Journal of Clinical Oncology
Funda Meric-Bernstam
Mansoor N. Saleh
Jeffrey R. Infante
Sanjay Goel
G. S. Falchook
Geoffrey I. Shapiro
Ki Y Chung
Robert M. Conry
David S. Hong
Judy Sing-Zan Wang
Ulrich Steidl
Loren D. Walensky
Vincent Guerlavais
Marie Payton
D. Allen Annis
Manuel Aivado
Manish R. Patel
Show All
Source
Cite
Save
Citations (55)
1